Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Business Summary
Number of employees: 3
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 22/03/22 | |
James Grainer
CHM | Chairman | 69 | 22/20/22 |
Lois Chandler
COO | Chief Operating Officer | - | 01/10/01 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 22/20/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 22/03/22 | |
James Grainer
CHM | Chairman | 69 | 22/20/22 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 22/20/22 |
Kaushik Vyas
BRD | Director/Board Member | 68 | 22/20/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 64,931,888 | 60,931,888 ( 93.84 %) | 0 | 93.84 % |
Stock B | 0 | 498 | 0 | 0 |
Company contact information
Taxus Cardium Pharmaceuticals Group, Inc.
11230 Sorrento Valley Road Suite 220
92121, San Diego
+858 414 1477
http://www.genebiotherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
0.00% | 64 | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+46.96% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- CRXM Stock
- Company Gene Biotherapeutics, Inc.